Suppliers / Amneal

Amneal

India AMRX Updated 9 July 2026

Amneal is a finished-dose manufacturer based in India. It holds one active US drug master file. Its filings concentrate with US FDA, INFARMED (PT) and MPA (SE). Its GMP standing is certified by US FDA, EMA and TMDA (TZ). Its most recent recorded inspection, by US FDA, closed on 28 March 2025 as NAI.

1
active US DMFs
0
valid CEPs
12
registered plants 10 with an FDA FEI number
665
filings across 14 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
10 of 10 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 28 March 2025 NAI US FDA
  • 30 August 2024 NAI US FDA
  • 19 July 2024 NAI US FDA
  • 19 June 2024 NAI US FDA
  • 8 February 2024 NAI US FDA
  • 21 November 2023 NAI US FDA
  • 14 July 2023 NAI US FDA
  • 9 June 2023 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Jadcherla, United Arab Emirates Not on file
Dist.-Ahmedabad, United Arab Emirates Not on file
Mehsana, India 3018907202
Ahmedabad, India 3017573557
Ahmedabad, India 3030461061
Ahmedabad, India 3029456823

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Glatiramer US FDA 1

Also appears on these molecule pages

Show 80 more molecule pages
Budesonide finished dose Calcitriol finished dose Carbidopa finished dose Carvedilol finished dose Cetirizine finished dose Chlorthalidone finished dose Ciprofloxacin finished dose Citalopram finished dose Clindamycin finished dose Clobetasol finished dose Codeine finished dose Dexamethasone finished dose Dextromethorphan finished dose Dutasteride finished dose Escitalopram finished dose Estradiol finished dose Finasteride finished dose Furosemide finished dose Gabapentin finished dose Glimepiride finished dose Guaifenesin finished dose Hydrochlorothiazide finished dose Hydroxyzine finished dose Ibuprofen finished dose Indomethacin finished dose Irbesartan finished dose Itraconazole finished dose Lamotrigine finished dose Levetiracetam finished dose Levodopa finished dose Levofloxacin finished dose Lorazepam finished dose Losartan finished dose Memantine finished dose Meropenem finished dose Mesalamine finished dose Mesalazine finished dose Metformin finished dose Methylprednisolone finished dose Metronidazole finished dose Mirtazapine finished dose Mometasone finished dose Montelukast finished dose Mycophenolate Mofetil finished dose Nitrofurantoin finished dose Norethisterone finished dose Nystatin finished dose Ofloxacin finished dose Olanzapine finished dose Olopatadine finished dose Oxcarbazepine finished dose Oxybutynin finished dose Paracetamol finished dose Paroxetine finished dose Phenylephrine finished dose Phenytoin finished dose Pioglitazone finished dose Pramipexole finished dose Progesterone finished dose Propofol finished dose Pyridostigmine finished dose Risperidone finished dose Ritonavir finished dose Rosuvastatin finished dose Saxagliptin finished dose Sildenafil finished dose Simvastatin finished dose Spironolactone finished dose Sucralfate finished dose Tamsulosin finished dose Telmisartan finished dose Terbinafine finished dose Ticagrelor finished dose Timolol finished dose Tobramycin finished dose Topiramate finished dose Tramadol finished dose Valsartan finished dose Verapamil finished dose Zolmitriptan finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 459 6
INFARMED (PT) 88 None
MPA (SE) 69 None
DIGEMAPS (DO) 11 None
ARCSA (EC) 7 None
JFDA (JO) 7 None
EMA None 1
TMDA (TZ) None 1

Scale

Year Revenue Exports Destinations
2017 $0 Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Amneal comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 98 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 28 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported